Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation reports developments tied to its food safety and animal safety businesses, including diagnostic tests, environmental monitoring products, veterinary products and related manufacturing operations. Company updates commonly cover foodborne pathogen detection, Listeria testing, AOAC method certification, Petrifilm manufacturing activity, and product quality or recall matters involving animal health products.
Neogen news also includes quarterly operating results, segment performance in Food Safety and Animal Safety, business transformation updates, leadership and compliance appointments, and governance matters. Its recurring disclosures connect scientific validation, manufacturing execution, customer markets and regulatory interactions across food safety, livestock, and pet health and wellness applications.
Neogen (NEOG) will release its first-quarter earnings after the market closes on October 6, 2026.
Company executives will host a webcast and conference call at 4:30 p.m. Eastern time to discuss the results. The live webcast will be available via Neogen’s Investor Relations webpage under “Events & Presentations,” and a replay of both the call and webcast will be accessible shortly after the event through the same site and dedicated replay phone lines.
Neogen (NEOG) will host an Investor Day on October 7, 2026, at 9 a.m. ET in New York City.
The event will focus on Neogen’s strategic transformation, including its commercial capabilities, innovation efforts, and operational excellence aimed at improving financial performance and long-term profitable growth. Senior executives, including the CEO, CFO and business unit leaders, will present and then take part in a Q&A session. A live webcast, presentation materials and a replay will be available on Neogen’s Investor Relations website.
Neogen (NASDAQ: NEOG) reported fiscal Q4 2026 revenue of $225.3 million, down 0.1% year over year, with core growth of 4.3%. Full-year 2026 revenue was $870.4 million, a decline of 2.7%, and core growth of 1.9%.
Q4 Food Safety revenue rose 3.1% (core +5.8%), led by Indicator Testing & Culture Media (+9.5%) and Bacterial & General Sanitation (+9.9%). Animal Safety revenue fell 8.2% but grew over 7% sequentially as supply issues eased. Q4 gross margin improved to 47.8% from 41.2%, with adjusted gross margin at 49.7%.
Neogen posted a Q4 net loss of $11.3 million (EPS $(0.05)), versus a $612.2 million loss a year ago. Q4 adjusted net income was $18.7 million (EPS $0.09). Adjusted EBITDA reached $45.4 million with a 20.2% margin. The company is progressing on its Petrifilm manufacturing transition and expects the first fully validated SKU by August 2026.
Neogen continues to work toward selling its global Genomics business to Zoetis for $160 million (about $140 million net, primarily for debt reduction). For FY27, it guides revenue to $880–$885 million and adjusted EBITDA to $180–$182 million, including estimated Genomics contributions, and Q1 FY27 revenue of $207–$209 million with adjusted EBITDA of about $37 million.
Neogen (NASDAQ: NEOG) will release its fourth-quarter fiscal year 2026 financial results before the market opens on Thursday, July 30, 2026. Company executives will host a webcast and conference call at 8:00 a.m. Eastern time to provide a financial overview and business update. Investors can access the call via toll-free and international dial-in numbers using Conference ID 741 914 740, or through the Investor Relations section of Neogen’s website, where a replay will be available after the event.
Neogen (NASDAQ: NEOG) expanded availability of FIFRA Section 2(ee) recommendations for Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol to support New World Screwworm response efforts.
Texas has approved these uses, and Neogen is making recommendations available in Florida to aid livestock and horse owners’ fly management programs.
Neogen (NASDAQ: NEOG) announced AOAC Performance Tested Methods℠ certification (No. 042604) for its Molecular Detection Assay - Listeria Right Now™, validating enrichment-free detection of viable and non-viable Listeria species on stainless steel.
The test delivers actionable results in about two hours, integrates with existing environmental monitoring workflows, and expands Neogen’s validated pathogen-detection portfolio.
Neogen (NASDAQ: NEOG) reported fiscal Q3 2026 revenue of $211.2M, down 4.4% year-over-year, with Food Safety up 2.6% and Animal Safety down 20.1% due to third-party supplier challenges. GAAP net loss was $17.0M (EPS $(0.08)); Adjusted EPS was $0.09. Adjusted EBITDA was $48.2M (22.8% margin). The company raised FY26 revenue guidance to $857–$860M and maintained Adjusted EBITDA guidance of ~$175M. Petrifilm manufacturing transition remains on track for November FY27 and a $160M Genomics divestiture to Zoetis is expected to close in 2Q27, with net proceeds ~$140M.
Neogen (NASDAQ:NEOG) appointed Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary effective immediately. Ms. Stacey brings more than 25 years of life sciences legal and compliance experience, including over 10 years as a public company chief legal officer and 5 years as a public company board member.
She previously served at Galera Therapeutics and held senior legal roles at Wistar Institute, Antares Pharma, FXI, Auxilium, and Aventis Behring. Ms. Stacey also serves on the board of Context Therapeutics (NASDAQ:CNTX).
Neogen (NASDAQ: NEOG) will release third-quarter fiscal 2026 results before market open on April 9, 2026. Management will host a webcast and conference call the same morning at 8:00 a.m. Eastern to provide a financial overview and business update.
Access details include toll-free and international dial-in numbers, a conference ID, and a live webcast via the company’s Investor Relations webpage; a replay will be available after the call.
Zoetis (NYSE: ZTS) will acquire Neogen's animal genomics business for $160 million, enhancing its Precision Animal Health capabilities.
The purchase adds five global laboratories, expanded genotyping and sequencing platforms, and software tools; Zoetis expects to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.